A Real World Study on Adjuvant Nivolumab: Recurrence Free Survival and Toxicity in Resected Stage III and IV Melanoma

被引：0
|
作者：
Huang, Wendy E. [1 ]
Archer, Christine [1 ]
Yip, Desmond [1 ,2 ]
Kanjanapan, Yada [1 ,2 ]
Peters, Geoffrey [1 ,2 ]
机构：
[1] Canberra Hosp, Dept Med Oncol, Garran, ACT, Australia
[2] Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
324
引用
下载
收藏
页码：173 / 174
页数：2
相关论文
共 50 条
  • [41] Real-world outcomes of nivolumab in adjuvant melanoma treatment in Australia
    Atkinson, Victoria
    Brady, Benjamin
    Peters, Geoffrey
    Azer, Mary
    Bakharevski, Olga
    McDonald, Laura
    Vouk, Katja
    Parente, Phillip
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 34 - 35
  • [42] Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
    Weber, J. S.
    Del Vecchio, M.
    Mandala, M.
    Gogas, H.
    Arance, A. M.
    Dalle, S.
    Cowey, C. L.
    Schenker, M.
    Grob, J. J.
    Chiarion-Sileni, V.
    Marquez-Rodas, I.
    Butler, M. O.
    Maio, M.
    Middleton, M. R.
    Tang, T.
    Saci, A.
    De Pril, V.
    Lobo, M.
    Larkin, J. M. G.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2019, 30 : 533 - +
  • [43] Adjuvant Chemoradiotherapy in Patients With Stage III or IV Radically Resected Gastric Cancer A Pilot Study
    Orditura, Michele
    De Vita, Ferdinando
    Muto, Paolo
    Vitiello, Fabiana
    Murino, Paola
    Lieto, Eva
    Vecchione, Loredana
    Romano, Anna
    Martinelli, Erika
    Renda, Andrea
    Ferraraccio, Francesca
    Del Genio, Alberto
    Ciardiello, Fortunato
    Galizia, Gennaro
    ARCHIVES OF SURGERY, 2010, 145 (03) : 233 - 238
  • [44] Impact of adjuvant immunotherapy on survival of patients with resected stage III melanoma diagnosed in 2003-2011 in the US
    Jang, S.
    Wang, H.
    Venna, S.
    MELANOMA RESEARCH, 2016, 26 : E8 - E9
  • [45] Beneficial Effect of Adjuvant Dabrafenib Plus Trametinib on Recurrence-Free Survival in Patients With Resected BRAFV600-Mutant Stage III Melanoma Seems to be Short-Lived
    Hess, Kenneth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15) : 1354 - +
  • [46] An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).
    Mandala, Mario
    Larkin, James M. G.
    Ascierto, Paolo Antonio
    Del Vecchio, Michele
    Gogas, Helen
    Cowey, C. Lance
    Fernandez, Ana Maria Arance
    Dalle, Stephane
    Schenker, Michael
    Grob, Jean Jacques
    Chiarion-Sileni, Vanna
    Marquez-Rodas, Ivan
    Butler, Marcus
    Di Giacomo, Anna Maria
    Middleton, Mark R.
    Lutzky, Jose
    Millward, Michael
    de Pril, Veerle
    Lobo, Maurice
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
    Blank, Christian U.
    Rozeman, Elisa A.
    Fanchi, Lorenzo F.
    Sikorska, Karolina
    van de Wiel, Bart
    Kvistborg, Pia
    Krijgsman, Oscar
    van den Braber, Marlous
    Philips, Daisy
    Broeks, Annegien
    van Thienen, Johannes, V
    Mallo, Henk A.
    Adriaansz, Sandra
    ter Meulens, Sylvia
    Pronk, Loes M.
    Grijpink-Ongering, Lindsay G.
    Bruining, Annemarie
    Gittelman, Rachel M.
    Warren, Sarah
    van Tinteren, Harm
    Peeper, Daniel S.
    Haanen, John B. A. G.
    van Akkooi, Alexander C. J.
    Schumacher, Ton N.
    NATURE MEDICINE, 2018, 24 (11) : 1655 - +
  • [48] MODELLING SURVIVAL OF PATIENTS WITH COMPLETELY RESECTED ADVANCED MELANOMA WITH ADJUVANT TREATMENT OF NIVOLUMAB VERSUS OBSERVATION
    Batteson, R.
    Hemstock, M.
    Hart, R.
    Kotapati, S.
    Gooden, K. M.
    Amadi, A.
    VALUE IN HEALTH, 2018, 21 : S359 - S359
  • [49] Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
    Christian U. Blank
    Elisa A. Rozeman
    Lorenzo F. Fanchi
    Karolina Sikorska
    Bart van de Wiel
    Pia Kvistborg
    Oscar Krijgsman
    Marlous van den Braber
    Daisy Philips
    Annegien Broeks
    Johannes V. van Thienen
    Henk A. Mallo
    Sandra Adriaansz
    Sylvia ter Meulen
    Loes M. Pronk
    Lindsay G. Grijpink-Ongering
    Annemarie Bruining
    Rachel M. Gittelman
    Sarah Warren
    Harm van Tinteren
    Daniel S. Peeper
    John B. A. G. Haanen
    Alexander C. J. van Akkooi
    Ton N. Schumacher
    Nature Medicine, 2018, 24 : 1655 - 1661
  • [50] BrUOG 324: Adjuvant nivolumab and low-dose ipilimumab for stage IIC, III, and resected stage IV melanoma: A phase II Brown University Oncology Research Group trial.
    Constantinou, Maria
    Vezeridis, Michael P.
    Weinstock, Martin A.
    Walker, Joanna
    Miner, Thomas J.
    Barth, Peter
    Rosati, Kayla
    Mitchell, Kristen
    Dionson, Sopha
    Turchetti, Wendy
    Vatkevich, John
    Rafelson, William Matthew
    Mantripragada, Kalyan C.
    Safran, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
12345